Saxagliptin
- Generic Name
- Saxagliptin
- Brand Names
- Kombiglyze, Komboglyze, Onglyza, Qtern, Qternmet
- Drug Type
- Small Molecule
- Chemical Formula
- C18H25N3O2
- CAS Number
- 361442-04-8
- Unique Ingredient Identifier
- 8I7IO46IVQ
- Background
Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.
- Indication
Treatment of type 2 diabetes mellitus to improve glycemic control in combination with other agents or as monotherapy.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study
- Conditions
- Interventions
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2019-08-14
- Target Recruit Count
- 56
- Registration Number
- NCT02613897
- Locations
- 🇺🇸
The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
Safety and Efficacy of Acarbose+Saxagliptin Compared With Metformin+Saxagliptin in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2015-11-16
- Last Posted Date
- 2015-11-18
- Target Recruit Count
- 100
- Registration Number
- NCT02605772
Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2015-11-05
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- Nick Giannoukakis, PhD
- Target Recruit Count
- 14
- Registration Number
- NCT02597101
- Locations
- 🇺🇸
Allegheny Health Network, Pittsburgh, Pennsylvania, United States
Saxagliptin and Cardiac Structure and Function
- Conditions
- Interventions
- First Posted Date
- 2015-06-25
- Last Posted Date
- 2020-03-30
- Lead Sponsor
- Unity Health Toronto
- Target Recruit Count
- 18
- Registration Number
- NCT02481479
- Locations
- 🇨🇦
St Michael's Hospital, Toronto, Ontario, Canada
Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea
- First Posted Date
- 2015-06-15
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 939
- Registration Number
- NCT02471404
- Locations
- 🇸🇰
Research Site, Vrutky, Slovakia
Saxagliptin's Effects on Microalbuminuria Improvement in Type 2 Diabetic Patients
- Conditions
- Interventions
- First Posted Date
- 2015-06-04
- Last Posted Date
- 2015-07-28
- Target Recruit Count
- 88
- Registration Number
- NCT02462369
A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone
- Conditions
- Interventions
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2020-06-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 444
- Registration Number
- NCT02419612
- Locations
- 🇬🇧
Research Site, Dundee, United Kingdom
Protective Effects of Saxagliptin (And Vitamin D3) on β Cell Function in Adult-onset Latent Autoimmune Diabetes
- Conditions
- Interventions
- First Posted Date
- 2015-04-03
- Last Posted Date
- 2021-04-20
- Target Recruit Count
- 300
- Registration Number
- NCT02407899
- Locations
- 🇨🇳
Gansu Provincial Hospital, Lanzhou, Gansu, China
🇨🇳Guangdong General Hospital, Guangzhou, Guangdong, China
🇨🇳Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China
Study on Exploring the Effect of DPP-4 Inhibitors on β-cell Function by Using the Two-step Hyperglycemic Clamp
- First Posted Date
- 2015-03-12
- Last Posted Date
- 2015-03-12
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 12
- Registration Number
- NCT02386943
- Locations
- 🇨🇳
Shanghai Jiao Tong University School of Medicine, Shanghai, China
Combining Saxagliptin and Acarbose to Improve Postprandial Glycaemia in Type 2 Diabetes
- First Posted Date
- 2014-12-12
- Last Posted Date
- 2018-07-06
- Lead Sponsor
- Zilin Sun
- Target Recruit Count
- 22
- Registration Number
- NCT02315495
- Locations
- 🇨🇳
Department of Endocrinology, Zhongda Hospital. Institute of Diabetes, Southeast University, Nanjing, Jiangsu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.